Pharmaceutical

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest Founder and CEO of Numinus, will participate in two upcoming investor conferences:

  • Sequire Cannabis & Psychedelic Conference to be held virtually on Wednesday, April 20, 2022 . Mr. Nyquvest will present at 1:00 p.m. ET . To attend, register here .

  • KCSA Psychedelics Investor Conference to be held virtually on April 27-28, 2022 . Mr. Nyquvest will present on Wednesday, April 27 th at 1:00 p.m. ET . To attend, register here .

For more information about the conferences, or to schedule a one-on-one meeting with Numinus' management, please contact your appropriate representative directly, or send an email to KCSA Strategic Communications NuminusIR@kcsa.com .

About Numinus

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn , Facebook , Twitter , and Instagram .

Forward-looking statements

Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

Cision View original content: https://www.prnewswire.com/news-releases/numinus-to-participate-in-upcoming-investor-conferences-in-april-2022-301519421.html

SOURCE Numinus Wellness Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/April2022/07/c5660.html

News Provided by Canada Newswire via QuoteMedia

NUMI:CA
Numinus to expand state-of-the-art psychedelics research laboratory

Numinus to expand state-of-the-art psychedelics research laboratory

Numinus Bioscience adds research space, enhances contract services,
accelerates IP development and increases psychedelic supply capacity

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), is pleased to announce plans to significantly expand its psychedelics research laboratory by late 2021.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Regulatory approvals place Numinus lab at the forefront of global psychedelics research

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada's Controlled Drugs and Substances Act that enhance the Company's ability to lead psychedelics research and support the global psychedelics sector.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access 1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC) a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research
capabilities ensure Numinus' continued growth

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and delivering psychedelic-centred solutions to treat mental illness, substance abuse and trauma, today announced its financial results for the first quarter for the three months ended November 20, 2020 ("Q1 2021"). After achieving two industry firsts, launching new compassionate access trials, and augmenting its clinical and research activity, Numinus meaningfully expanded its industry presence in Q1 2021. All financial results are reported in Canadian dollars unless otherwise stated.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf International Announces Landmark Product Registration in Poland

Latest Move Marks Continued Expansion of European Footprint in Growing Medical Cannabis Market

Curaleaf International (the "Company") part of Curaleaf Holdings (CNSX:CURA), Europe's largest vertically integrated cannabis company, is pleased to announce the successful registration of the Company's cannabis based medicines as extract in Poland, with local partner CanPoland S.A.. Poland is one of the largest medical cannabis markets in Europe by patient population 1 , with a market size expected to be worth at least €2 billion by 2028 2 .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Curaleaf Announces Majority Stake and Forms Strategic Partnership with Germany's Four 20 Pharma, a Fully EU-GMP & GDP Licensed Producer and Distributor of Medical Cannabis

Deal Bolsters Curaleaf Presence and Cements Strategic Advantage in Europe's Largest Market as Germany Readies for Adult Use

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today announced that Curaleaf International Holdings Limited, the company's European holding company, has signed a definitive agreement to acquire a 55% stake in Four 20 Pharma GmbH, a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis with its own product line.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cronos Group Reports 2022 Second Quarter Results

Consolidated net revenue increased by 48% year-over-year to $23.1 million in Q2 2022

Israel net revenue increased by 212% year-over-year to $7.2 million in Q2 2022

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
money being thrown away in a wastebasket

Cannabis Waste Hits Record in Canada, How Should Investors Act?

As product destruction from Canadian cannabis operators continues to climb to new heights, how should investors perceive this mounting waste?

New figures from Health Canada, first reported by MJBizDaily, show Canadian cannabis producers destroyed 425 million grams of licensed cannabis last year. On top of that, over 7 million packaged products were destroyed.

The record number of cannabis products destroyed in 2021 was even more than what was sold in the first year of adult-use legalization in Canada, as per the report.

Keep reading...Show less

Curaleaf Reports Second Quarter 2022 Results

Second Quarter 2022 Revenue of $338 Million , an increase of 8% sequentially and YoY

Second Quarter 2022 Adjusted EBITDA (1) of $86 Million , an increase of 18% sequentially and 2% YoY

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Curaleaf Bolsters Executive Leadership Team with Three Key Hires

Ed Kremer Joins as Chief Financial Officer, Camilo Lyon is Named Chief Investment Officer and Mitch Hara Fills New Role of Chief Strategy Officer

- Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, has announced three new hires joining the company's executive leadership team this month. Ed Kremer will join as Chief Financial Officer, Camilo Lyon was named Chief Investment Officer, and Mitch Hara will be Chief Strategy Officer, a new role at the company. Mr. Kremer and Mr. Lyon will begin August 8 and Mr. Hara joined effective August 3 .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×